risankizumab
abbvie
[' psa', 'risan']
52 week risankizumab in psa. at week 52, 55% with enthesitis resolution (lei = 0), 76.1% with dactylitis resolution (ldi = 0), and 52.3% with both enthesitis and dactylitis (lei and ldi = 0). nice tool to have! #acr22
Rheumatologist, person.  Views expressed here do not reflect those of my employer.  @PennRheum